Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 15289844 | HLA-A*02 | prostate cancer | NA | NA | NA | unclassified | |
| these 2 candidates effectively induced hla-a2-restricted and prostate cancer-reactive ctls in hla-a2+ prostate cancer patients with several hla-a2 subtypes. | |||||||
| 15289844 | HLA-A*02 | prostate cancer | NA | NA | NA | unclassified | |
| these results indicate that these psma441-450 and pap112-120 peptides could be promising candidates for peptide-based immunotherapy for hla-a2(+) prostate cancer. | |||||||
| 15378520 | HLA-A*24 | phosphate | NA | estramustine | NA | only_studied | |
| NA | |||||||
| 15378520 | HUMAN LEUKOCYTE ANTIGEN (HUMAN LEUKOCYTE ANTIGEN) | phosphate | NA | estramustine | NA | only_studied | |
| NA | |||||||
| 16000955 | HLA-A*24 | prostate cancer | NA | NA | NA | only_studied | |
| the authors studied humoral and cd4+ t-cell responses in an hla-a24+ prostate cancer patient vaccinated with cytotoxic t lymphocyte (ctl)-directed peptides, including a prostate-specific antigen (psa)248-257 peptide, to understand what kinds of immune responses are elicited in peptide-vaccinated patients. | |||||||
| 16203785 | HLA-A*03 | prostate cancer | NA | NA | NA | only_studied | |
| identification of peptide vaccine candidates for prostate cancer patients with hla-a3 supertype alleles. | |||||||
| 16203785 | HLA-A*33 | prostate cancer | NA | NA | NA | unclassified | |
| in this study, we attempted to identify ctl-directed peptide candidates, derived from prostate-related antigens and shared by hla-a11+, hla-a31+, and hla-a33+ prostate cancer patients. | |||||||
| 16203785 | HLA-A*31 | prostate cancer | NA | NA | NA | unclassified | |
| in this study, we attempted to identify ctl-directed peptide candidates, derived from prostate-related antigens and shared by hla-a11+, hla-a31+, and hla-a33+ prostate cancer patients. | |||||||
| 16203785 | HLA-A*11 | prostate cancer | NA | NA | NA | unclassified | |
| in this study, we attempted to identify ctl-directed peptide candidates, derived from prostate-related antigens and shared by hla-a11+, hla-a31+, and hla-a33+ prostate cancer patients. | |||||||
| 16203785 | HLA-A*33 | prostate cancer | NA | NA | NA | unclassified | |
| these peptides were first screened for their ability to be recognized by immunoglobulin g (igg) of prostate cancer patients and subsequently for the potential to induce peptide-specific and prostate cancer-reactive ctls from peripheral blood mononuclear cells (pbmc) of cancer patients with the hla-a11, hla-a31, and hla-a33 alleles. | |||||||
Copyright 2024